Clinical trials: Fatty Acid Metabolism
Major Depression, Cancer
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions…
- Conditions
- Major Depression, Cancer, Diabetes, Cardiovascular Diseases
- Trial name
- NCT01803711
- Testing
- Desvenlafaxine, Omega 3 Fatty acids
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UConn Health
Type 2 Diabetes Mellitus, Obesity
Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus
Muscle insulin resistance is a hallmark of upper body obesity (UBO) and Type 2 diabetes (T2DM). It is unknown whether muscle free fatty acid (FFA) availability or intramyocellular fatty acid trafficking is responsible for the…
- Trial name
- NCT03867500
- Testing
- Niacin, Saline
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Hypertriglyceridemia
Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia
This study will build upon a previous finding that showed a triglyceride lowering effect of prescription omega-3 in combined therapy with statins.
- Trial name
- ELLF (NCT00959842)
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sanford Research
Type 2 Diabetes, Dyslipidemia
Effects of Metformin on Hepatic FFA Metabolism
Background: Metformin treatment has beneficial effects on both glucose and lipid metabolism. Whereas there is general agreement that the blood glucose lowering effect of metformin results from inhibition of hepatic…
- Trial name
- NCT01729156
- Testing
- Metformin
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Lars Christian Gormsen
Nonalcoholic Steatohepatitis
Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)
This Phase 2, double-blind, randomized, placebo-controlled, multicenter study, with an open-label long-term safety extension (LTSE), will evaluate the effect of Obeticholic Acid, and the subsequent addition of statin therapy, on…
- Trial name
- CONTROL (NCT02633956)
- Testing
- Obeticholic Acid, Atorvastatin
- Where
- 22 sites in United States
- Volunteers
- 84 people
- Sponsor
- Intercept Pharmaceuticals
Familial Partial Lipodystrophy
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
Lipodystrophies are rare disorders characterized by selective loss of adipose tissue and predisposition to insulin resistance and its metabolic complications.
- Trial name
- NCT02430077
- Testing
- Obeticholic Acid
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Abhimanyu Garg
Major Depressive Disorder, Overweight
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
This project aims to evaluate whether a dose-response relationship exists between dose of polyunsaturated fatty acids (PUFA), delivered as eicosapentaenoic acid (EPA), and change in markers of inflammation, and whether these…
- Conditions
- Major Depressive Disorder, Overweight, Inflammation
- Trial name
- NCT02553915
- Testing
- EPA 1 g/day, EPA 2 g/day, EPA 4 g/day
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Non-Insulin-Dependent
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
The primary objectives of the ORIGIN study were: To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired…
- Trial name
- ORIGIN (NCT00069784)
- Testing
- insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), reusable pen device for insulin injection
- Where
- 40 sites in United States, Argentina and 38 more
- Volunteers
- 12,537 people
- Sponsor
- Sanofi
Fatty Liver
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver
Non-alcoholic steatohepatitis (NASH), the most severe form of liver injury in the spectrum of non-alcoholic fatty liver disease (NAFLD), has emerged as the major cause of chronic liver disease in developed countries.
- Trial name
- NCT00323414
- Testing
- Polyunsaturated fatty acid (Opti-EPA)
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Bilirubin Encephalopathy
Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration
The purpose of this study is to evaluate the effect of usual versus reduced lipid intake on unbound bilirubin levels, brainstem auditory evoked responses, and neurodevelopmental outcome at 2 years in extremely preterm infants.
- Trial name
- NCT04584983
- Testing
- usual prescribed intralipid (UL) regimen, restricted prescribed intralipid (RL) regimen
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- The University of Texas Health Science Center, Houston
Healthy
Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma Fatty Acids
Background: As the main alternative fuel to glucose for the brain, increased plasma ketones could potentially help compensate for brain glucose hypometabolism occurring during aging.
- Trial name
- NCT02410161
- Testing
- alpha-linolenic acid-rich supplement
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Critical Illness, Hyperglycemia
Effects of a Complete Diet in Critically Ill Patients With Stress Hyperglycemia
The aim of the study is to evaluate the beneficial effects of the administration of a complete diet rich in monounsaturated fatty acids (MUFA) and slow absorption carbohydrate in patients with stress hyperglycemia(T-Diet Plus…
- Conditions
- Critical Illness, Hyperglycemia, Dietary Modification, Metabolic Stress Hyperglycemia
- Trial name
- NCT01233726
- Testing
- T-Diet plus Diabet IR, ISOSOURCE PROTEIN FIBRE, GLUCERNA SELECT
- Where
- 2 sites in Spain
- Volunteers
- 159 people
- Sponsor
- Vegenat, S.A.
Lysosomal Acid Lipase Deficiency
Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D). Eligible participants received once-weekly infusions of sebelipase alfa for up to 3 years.
- Trial name
- NCT02193867
- Testing
- Sebelipase Alfa
- Where
- 5 sites in United States, Finland and 2 more
- Volunteers
- 10 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Diabetes Mellitus, Type II
Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Type 2 Diabetes Mellitus (T2DM) is a disease that interferes with the body's proper production and use of insulin, a hormone needed to convert sugar into usable energy.
- Trial name
- T2DM (NCT00577590)
- Testing
- Metformin, Rosiglitazone, Lovaza
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Washington University School of Medicine
Hyperlipidemia
Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3
The purpose of this survey is to determine the incidence rate of cardiovascular (CV) events associated with long-term treatment with and without omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) in high-risk…
- Trial name
- NCT02285166
- Testing
- Omega-3 fatty acid ethyl esters, Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).
- Where
- 2 sites in Japan
- Volunteers
- 15,330 people
- Sponsor
- Takeda
Prediabetes, Obesity
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
This project addresses cardiovascular disease risk in patients with prediabetes. Levels of lipids after eating a meal ("postprandial lipids") are strong independent predictors of cardiovascular risk.
- Trial name
- NCT02104739
- Testing
- Exenatide, Saxagliptin, Exenatide extended-release (ER)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Obesity, Leptin Resistance
Effect of Increased Free Fatty Acids on Leptin Function
Obese people have elevated levels of the hormone leptin. Despite this, they seem to be resistant to the effects of this hormone, which usually regulates appetite and energy expenditure.
- Trial name
- NCT01520454
- Testing
- Saline, Intralipid, Water
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Type 2 Diabetes
Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids…
- Trial name
- NCT01633177
- Testing
- Vitamin D3, Omega-3 fatty acid (fish oil)
- Where
- United States
- Volunteers
- 22,220 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Inflammation, Insulin Resistance
Mechanisms of Insulin Resistance in Humans
The Objectives of the study are to: (1)compare the inflammatory response and insulin resistance in skeletal muscles during a systemic infusion of lipid with that during a local infusion of lipid into the femoral artery.
- Trial name
- NCT00330967
- Testing
- 20% Intralipid
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Insulin Resistance
Omega-3 Fatty Acids and Insulin Sensitivity
This study is being done to understand the effects of dietary omega-3 fats on insulin sensitivity in adult men and women.
- Trial name
- NCT01686568
- Testing
- Omega-3
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic